NASDAQ:ABMDABIOMED Stock Price, Forecast & News

ABIOMED's stock was trading at $151.13 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ABMD stock has increased by 78.1% and is now trading at $269.15. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for ABIOMED.

ABIOMED is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for ABIOMED.

ABIOMED, Inc. (NASDAQ:ABMD) announced its quarterly earnings data on Thursday, April, 30th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.96 by $0.26. The medical equipment provider had revenue of $206.66 million for the quarter, compared to analyst estimates of $209.58 million. ABIOMED had a return on equity of 18.51% and a net margin of 24.14%. ABIOMED's revenue was down .2% on a year-over-year basis. During the same quarter last year, the firm earned $1.60 EPS. View ABIOMED's earnings history.

8 Wall Street analysts have issued 12 month target prices for ABIOMED's shares. Their forecasts range from $152.00 to $240.00. On average, they anticipate ABIOMED's share price to reach $193.00 in the next twelve months. This suggests that the stock has a possible downside of 28.3%. View analysts' price targets for ABIOMED.

Headlines about ABMD stock have trended negative this week, according to InfoTrie. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. ABIOMED earned a news impact score of -2.1 on InfoTrie's scale. They also assigned news coverage about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about ABIOMED.

ABIOMED saw a drop in short interest during the month of June. As of June 30th, there was short interest totaling 2,360,000 shares, a drop of 13.6% from the June 15th total of 2,730,000 shares. Based on an average daily volume of 559,700 shares, the short-interest ratio is currently 4.2 days. Currently, 5.4% of the company's stock are short sold. View ABIOMED's Current Options Chain.

Some companies that are related to ABIOMED include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Baxter International (BAX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Steris (STE) and Masimo (MASI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ABIOMED investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Align Technology (ALGN), Netflix (NFLX), Arista Networks (ANET), Square (SQ), Paypal (PYPL), salesforce.com (CRM) and Adobe (ADBE).

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

ABIOMED's stock is owned by a number of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.02%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Martin P Sutter and Michael G Howley. View institutional ownership trends for ABIOMED.

ABMD stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. View insider buying and selling activity for ABIOMED.

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ABMD stock can currently be purchased for approximately $269.15.

ABIOMED has a market capitalization of $12.12 billion and generates $840.88 million in revenue each year. The medical equipment provider earns $203.01 million in net income (profit) each year or $4.74 on an earnings per share basis. ABIOMED employs 1,536 workers across the globe.

The official website for ABIOMED is www.abiomed.com.

ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]